SCHEMBL29956492

SCHEMBL29956492

CCc1ccncc1B(O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 3/20 0.42
CYP2C8 P10632 3/20 0.42
CYP2D6 P10635 3/20 0.42
CYP2A6 P11509 3/20 0.42
CYP2B6 P20813 3/20 0.42
CYP2C19 P33261 3/20 0.42
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP3A4 P08684 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
AOC1 P19801 5/20 0.37
AOC3 Q16853 5/20 0.37
KDM5A P29375 2/20 0.36
LOXL2 Q9Y4K0 1/20 0.35
NAPRT Q6XQN6 1/20 0.35
LPL P06858 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
KDM6B O15054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20519975 1.00 CYP2E1 (0.42) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL29953418 0.84 CYP2E1 (0.45) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL6362005 0.84 CYP2E1 (0.45) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL18362685 0.82 LOXL2 (0.38) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL20519199 0.79 CYP11B2 (0.43) LMNAAOC1AOC3LOXL2
SCHEMBL28983721 0.79 CHRNB2 (0.43) CYP2D6CYP2A6CYP2C19CYP1A2CYP3A4
SCHEMBL20519418 0.77 GPBAR1 (0.36) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL20519210 0.76 ENPP2 (0.35) SMN1; SMN2AOC1AOC3LOXL2LIPG
SCHEMBL877689 0.75 CYP2E1 (0.48) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL15476059 0.74 AOC1 (0.31) AOC1AOC3LOXL2LIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A CYP2E1 3966/4885CYP2C8 4316/4885CYP2D6 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.